ALEXANDRIA, Va. and
DUBLIN, Feb. 9, 2017
/PRNewswire/ -- The American Association for the Study of Liver
Diseases (AASLD) Foundation, the largest private supporter of
hepatology research in the United
States, today announced a significant donation from Allergan
to support the AASLD Foundation's research and education
initiatives. With this donation, Allergan joins the AASLD
Foundation's Founder's Society, the premier donor recognition
circle established to honor the generosity and commitment of
companies who partner with AASLD Foundation to ensure more
resources for liver disease research and advanced hepatology
training. AASLD Foundation's Founder's Society companies have each
made commitments of $2 million or
more to support AASLD Foundation's mission to invest in innovative
hepatology research and in the people who study and treat liver
disease.
"AASLD Foundation is proud of the impact we are making," says
Bruce Bacon, MD, FAASLD, the AASLD
Foundation's board of trustees Chair. "In 2016, we invested
$2.63 million to fund the ideas of
bright young investigators and to provide training opportunities
for future hepatology leaders. However, we know there is so much
more to be done, and we are grateful that Allergan recognizes that,
too. This donation signifies Allergan's partnership in the fight
against liver disease and its desire for a long-term investment in
the discovery of innovative treatment options that promise improved
patient care as well as training more professionals to care for
liver disease patients. Their corporate philanthropy will help
reduce the annual gap of nearly $4
million needed to fully fund meritorious research and career
development awards over the next few years. This commitment will
also ensure new resources are created through initiatives like the
Foundation's Fundamentals of Liver Disease so more professionals
are trained to care for liver disease patients."
"Allergan is focused on identifying, developing and bringing
forward innovative treatments for patients with significant unmet
medical needs, including non-alcoholic steatohepatitis (NASH). The
Foundation's efforts in research and training are directly aligned
with several of the principles of Allergan's Social Contract with
Patients, making this an ideal organization for our philanthropy,"
says Gavin Corcoran, MD, FACP, Chief
Medical Officer, Allergan. "This donation underscores Allergan's
commitment to supporting research and educational initiatives that
advance medical innovation and the ability to save more lives,
which is possible through increased research and enhanced
hepatology training opportunities."
For more information about the AASLD Foundation, visit
aasldfnd.org. And, for more information about Allergan, visit
Allergan.com.
Allergan NASH Programs
Allergan has demonstrated category leadership in several
gastrointestinal disorders (GI) and shown continued commitment to
innovate and advance science and treatments for unmet medical
needs. Currently, NASH represents one of the greatest unmet medical
needs and is a natural and fluid extension of Allergan's broad GI
portfolio.
Late last year, Allergan acquired cenicriviroc (CVC), evogliptin
and AGN-242266 (formerly AKN-083), three differentiated,
complementary programs targeting different mechanisms for the
multi-factorial treatment of NASH. CVC is a first-in-class,
once-daily, oral Phase 3 ready, potent immunomodulator that blocks
two chemokine receptors, CCR2 and CCR5, which are involved in
inflammatory and fibrogenic pathways. AGN-242266 is a potentially
best-in-class preclinical farnesoid X receptor (FXR) agonist in
development for the treatment of NASH, and is highly complementary
to CVC and Evogliptin. Allergan is committed to advancing its
overall portfolio of NASH programs, to focus on bringing forward
effective treatments for this critical disease area.
About the AASLD Foundation
AASLD Foundation is a 501 (c)(3) charitable organization with a
mission of investing in innovative hepatology research and in the
people who study and treat liver disease. Visit aasldfnd.org to
learn more about our work, or aasldfnd.org/donate to support more
liver disease research and advanced hepatology training.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical company and a leader in a new industry model –
Growth Pharma. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceuticals, devices
and biologic products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, the Company's
R&D model, which defines our approach to identifying and
developing game-changing ideas and innovation for better patient
care. This approach has led to Allergan building one of the
broadest development pipelines in the pharmaceutical industry with
65+ mid-to-late stage pipeline programs in development.
Our Company's success is powered by our more than 16,000 global
colleagues' commitment to being Bold for Life. Together, we build
bridges, power ideas, act fast and drive results for our customers
and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website at
www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective of existing trends and
information as of the date of this release. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements. Actual results may differ
materially from Allergan's current expectations depending upon a
number of factors affecting Allergan's business. These factors
include, among others, uncertainty associated with the development
of commercially successful branded pharmaceutical products; the
difficulty of predicting the timing or outcome of product
development efforts and regulatory agency approvals or actions, if
any; the impact of competitive products and pricing; market
acceptance of and continued demand for Allergan's products;
difficulties or delays in manufacturing; and other risks and
uncertainties detailed in Allergan's periodic public filings with
the Securities and Exchange Commission, including but not limited
to Allergan's Annual Report on Form 10-K for the year ended
December 31, 2015 and Quarterly
Report on Form 10-Q for the quarter ended September 30, 2016. Except as expressly required
by law, Allergan disclaims any intent or obligation to update these
forward-looking statements.
Media Contacts:
Erin Meadows
703.299.9766
emeadows@aasld.org
Lisa DeFrancesco
Investor Relations
862.261.7152
lisa.defrancesco@allergan.com
Mark Marmur
Media Relations
862.261.7558
mark.marmur@allergan.com
Tara Schuh
Public Relations
201.427.8888
tara.schuh@allergan.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/aasld-foundations-liver-disease-research-and-education-initiatives-bolstered-by-significant-donation-from-allergan-300404642.html
SOURCE Allergan plc